Abstract
Immunoglobulin (Ig) isotypes G, M, and A of anticardiolipin antibodies (aCL) are considered markers of antiphospholipid syndrome (APS). They were determined by ELISA in sera of 100 healthy children aged between 6 months and 16 yrs (mean 5.4 yrs ± 3.4 SD) and 100 healthy elderly subjects aged between 65 and 103 yrs (mean 84.2 yrs ± 8.1 SD). The frequency with which they were detected was compared to that in sera of 100 healthy adults aged between 21 and 47 yrs (mean 25.8 yrs ± 5.2 SD) in order to evaluate if adult aCL cut‐off levels were fit for pediatric and elderly populations. The cut‐off points were calculated adding 2.5 SD to the mean values and, in the adult group, the results were 11.6 GPL, 7.5 MPL, and 23.9 APL for IgG, IgM, and IgA, respectively. In the children, IgG aCL were positive in 26 cases (26%), IgM and IgA aCL in 1 case (1%) respectively. Statistical comparison of these results to those of adults showed a higher significant frequency for children IgG aCL (P = 0.0001) with the major contribution by children aged between 6 months and 5 yrs, and a lower significant frequency for children IgA aCL (P = 0.041). In elderly subjects IgG aCL were positive in 12 cases (12%), IgM aCL in 4 (4%), and IgA aCL in 37 (37%). In a comparison of these values to those of adults, only elderly IgA aCL frequency was significantly higher (P = 0.0001) with the major contribution by the oldest subgroup. In order to avoid false positive results for IgG aCL in children and for IgA aCL in elderly, as well as false negative results for IgA aCL in children, we introduced three new cut‐off points: (1) 27.7 GPL for IgG aCL in children; (2) 13.8 APL for IgA aCL in children; and (3) 51.1 APL for IgA aCL in elderly subjects. These data suggest that a correction for age of aCL cut‐off levels should be considered to raise specificity and sensitivity for APS in pediatric as well as in elderly populations. J. Clin. Lab. Anal. 14:87–90, 2000. © 2000 Wiley‐Liss, Inc.
Keywords: anticardiolipin antibodies, antiphospholipid antibodies, ELISA, pediatric anticardiolipin antibodies, adult anticardiolipin antibodies, elderly anticardiolipin antibodies
REFERENCES
- 1. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non‐SLE disorders. Ann Intern Med 1990;112:682–698. [DOI] [PubMed] [Google Scholar]
- 2. Asherson RA, Block S, Houssiau FA, Hughes GRV. Systemic lupus erythematosus and lymphoma: association with antiphospholipid syndrome. J Rheumatol 1991;18:277–279. [PubMed] [Google Scholar]
- 3. Stiehm ER, Fulginiti VA. Immunologic disorders in infants and children. Philadelphia, London, Toronto: WB Saunders Company; 1980. 227 p. [Google Scholar]
- 4. Buckley CE, Buckley EG, Dorsey FC. Longitudinal changes in serum immunoglobulin levels in other humans. Fed Proc 1974;33:2036–2039. [PubMed] [Google Scholar]
- 5. Radl J, Sepers JM, Skvaril F, Morell A, Hijmans W. Immunoglobulins patterns of humans over 95 years of age. Clin Exp Immunol 1975; 22:84–90. [PMC free article] [PubMed] [Google Scholar]
- 6. Manoussakis MN, Tzioufas AG, Silis MP, Pange PJ, Goudevenos J, Moutsopoulos HM. High prevalence of anti‐cardiolipin and other autoantibodies in a healthy elderly population. Clin Exp Immunol 1987;69:557–565. [PMC free article] [PubMed] [Google Scholar]
- 7. Ruffatti A, Rossi L, Calligaro A, Del Ross T, Lagni M, Marson P, Todesco S. Autoantibodies of systemic rheumatic diseases in the healthy elderly. Gerontology 1990;36:104–111. [DOI] [PubMed] [Google Scholar]
- 8. Ligthart GJ, Corberand JX, Fournier C, et al. Admission criteria for immunogerontological studies in man: the SENIEUR protocol. Mech Aging Dev 1984;28:47–55. [DOI] [PubMed] [Google Scholar]
- 9. Solinger AM. Drug‐related lupus. Clinical and etiologic considerations. Rheum Dis Clin North Am 1988;14:187–202. [PubMed] [Google Scholar]
- 10. Harris EN. Antiphospholipid antibodies (Annotation). Brit J Haematol 1990;74:1–9. [DOI] [PubMed] [Google Scholar]
- 11. Vaarala O, Palosuo T, Kleemola M, Aho K. Anticardiolipin response in acute infections. Clin Immunol Immunopathol 1986;41(1):8–15. [DOI] [PubMed] [Google Scholar]
- 12. Barrile A, Quattrocchi P, Bonanno D, et al. Presence and significance of anticardiolipin antibodies in infactious diseases. Recenti Prog Med 1992;83(6):350–353. [PubMed] [Google Scholar]
- 13. Kanariou M, Petridou E, Liatsis M, Revinthi K, Mandalenaki‐Lambrou K, Trichopoulos D. Age patterns of immunoglobulins G, A and M in healthy children and the influence of breast feeding and vaccination status. Pediatr Allergy Immunol 1995;6(1):24–29. [DOI] [PubMed] [Google Scholar]
- 14. Ruffatti A, Calligaro A, Del Ross T, et al. Anti‐double‐stranded DNA antibodies in the healthy elderly: prevalence and characteristics. J Clin Immunol 1900;10:300–303. [DOI] [PubMed] [Google Scholar]
- 15. Derkesen RHWM. Clinical manifestation and management of the antiphospholipid syndrome. Lupus 1996;5:167–169. [DOI] [PubMed] [Google Scholar]
- 16. Ruffatti A, De Silvestro G, Ghirardello A, et al. A Catastrophic antiphosphilid syndrome: the importance of high levels of warfarin anticoagulation. J Intern Med 1994;235:81–83. [DOI] [PubMed] [Google Scholar]
- 17. Berstein ML, Salusinsky‐Sternbach M, Bellefleur M, Esseltine DW. Thrombotic and hemorragic complications in children with the lupus anticoagulant. Am J Dis Child 1984;138:1132–1135. [DOI] [PubMed] [Google Scholar]
- 18. Guariso G, Ruffatti A, Casonato A, Drigo P, Ghirardello A, Zancan L. Antiphospholipid syndrome in a child with trisomy 21: the relationship between anti‐cardiolipin G antibodies and the von Willebrand factor. Clin Exp Rheumatol 1992;10:613–616. [PubMed] [Google Scholar]
- 19. The Antiphospholipid Antibodies in Stroke Study Group . Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia. Stroke 1990;21: 1268–1273. [DOI] [PubMed] [Google Scholar]
- 20. Brey RL. Stroke prevention in patients with antiphospholipid antibodies. Lupus 1994;3:299–302. [DOI] [PubMed] [Google Scholar]